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Abstract 
 
Ethosuximide is the drug of choice for treating generalised absence seizures, but its 
mechanism of action is still a matter of debate. It has long been thought to act by 
disrupting a thalamic focus via blockade of T-type channels and thus generation of 
spike wave activity in thalamo-cortical pathways. However, there is now good 
evidence that generalised absence seizures may be initiated at a cortical focus and 
that ethosuximide may target this focus. In the present study we have looked at the 
effect ethosuximide on glutamate and GABA release at synapses in the rat 
entorhinal cortex in vitro, using two experimental approaches. Whole-cell patch 
clamp-studies revealed an increase in spontaneous GABA release by ethosuximide 
concurrent with no change in glutamate release. This was reflected in studies that 
estimated global background inhibition and excitation from intracellularly recorded 
membrane potential fluctuations, where there was a substantial rise in the ratio of 
network inhibition to excitation, and a concurrent decrease in excitability of neurones 
embedded in this network. These studies suggest that, in addition to well- 
characterised effects on ion channels, ethosuximide may directly elevate synaptic 
inhibition in the cortex and that this could contribute to its anti-absence effects. 
 
Key words: entorhinal cortex; ethosuximide; glutamate release, GABA release, 
excitability 
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1. Introduction 
Generalised, non-convulsive absence seizures are characterised by brief episodes 
of unconsciousness accompanied by synchronised bilateral spike and wave 
discharges (SWD). Ethosuximide is the drug of choice in the treatment of absence 
epilepsy (Posner et al., 2004; Glauser et al., 2010). It has a number of potential 
molecular targets, but its precise mechanism of action has not been elucidated.  
 
One view of the basis of absence epilepsy is that it involves an interaction between a 
hyperexcitable cortex and a rhythm generator operative via a thalamocortical loop, 
where rhythmical bursts of activity in the GABAergic neurones of the thalamic 
reticular nucleus play a central role (see Crunelli and Leresche, 2002a; Manning et 
al., 2003; Meeren et al., 2005). These bursts of activity are driven by low-threshold 
(T-type) Ca-currents, and it has been postulated that block of T-type Ca-channels in 
thalamocortical reticular nucleus neurones may be the basis of the anti-absence 
effects of ethosuximide (Coulter et al., 1989a,b; Kostyuk et al., 1992; Huguenard, 
1999; Gomora et al., 2001). However, there is still controversy over whether this 
blockade is the whole story (see Crunelli and Leresche, 2002b; Manning et al., 
2003). Certainly, ethosuximide is promiscuous in its effects and has been shown to 
block other ion channels (Leresche et al., 1998; Kobayashi et al., 2009).  
 
Early studies implicated the thalamus as a primary site of epileptogenesis, but 
increasing attention has centred on a cortical focus in absence seizures 
(Siedenbecher et al., 1998; Meeren et al, 2002; 2005; Holmes et al., 2004; Sadlier et 
al., 2006; Polack et al., 2007). It is possible that ethosuximide acts partially, or 
exclusively, at this level. A weak and delayed reduction of the spike-wave discharges 
in genetically epileptic rats followed infusion of ethosuximide directly into the 
thalamus, but systemic injection resulted in immediate cessation of discharges 
(Richards et al., 2003). Likewise, direct application into somatosensory cortex 
caused immediate cessation of discharges (Manning et al., 2004; Gülhan-Aker et al., 
2010). Polack et al. (2007) suggested that spike-wave discharges were initiated by 
pyramidal neurones layer V, and found that hyperexcitability in this region was 
normalised by systemic ethosuximide (Polack and Charpier, 2009). The molecular 
mechanism of this action of ethosuximide could involve actions at one or more of the 
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ion channel targets noted above but it is also feasible that alterations of inhibitory or 
excitatory synaptic transmission could be involved. For example, Luhman et al. 
(1994) showed an impairment of GABA inhibition in the cortex of WAG/Rij rats, a 
genetic model of absence epilepsy. Also, A number of mutations in GABAA-receptors 
(GABAAr) have been linked to childhood absences (see Galanopoulou, 2010; 
McDonald et al., 2010). One mutation, in the γ2 subunit, has been shown to elicit 
ethosuximide-sensitive absence seizures when expressed in mice, associated with a 
reduced expression of the subunit and a decrease in GABAAr mediated events in 
somatosensory cortex (Tan et al., 2007). Thus, cortical hyperexcitability could be 
associated with the loss of GABA inhibition and ethosuximide could target cortical 
GABA transmission in absence epilepsy. 
 
We have recently studied the effects of anticonvulsant drugs on excitatory and 
inhibitory transmission in the entorhinal cortex (EC). Using patch clamp recordings of 
spontaneous postsynaptic currents, we have studied the effects of the drugs on 
GABA and glutamate release (Cunningham et al., 2000; 2003; 2004; Cunningham 
and Jones, 2000; Yang et al., 2007). We have complemented these studies using a 
novel approach (Greenhill and Jones, 2007; 2010) to determine global, network 
driven, background excitation and inhibition, estimated from the distribution of resting 
membrane potential fluctuations (VmD) in individual neurones (see Rudolph et al., 
2004; 2007). We have studied a number of drugs used to treat tonic-clonic 
convulsive seizures, some of which are also used in absence epilepsies. Patch 
clamp studies revealed diverse effects on spontaneous of glutamate and GABA 
release, and these were reflected by global changes in excitation and inhibition 
determined by VmD studies. However, the drugs had the common effect of elevating 
the ratio between inhibition and excitation in favour of the former (Greenhill and 
Jones, 2010). Concurrently, they caused a decline in intrinsic neuronal excitability. 
 
We have now determined the effect of specific anti-absence drug, ethosuximide, on 
synaptic transmission and excitability in the rat EC. Whilst evidence suggests that 
the frontal and somatosensory cortex are likely foci in absence seizures (Meeren et 
al., 2002; Polack et al., 2007), EEG studies indicate that some absence and related 
seizures could originate at temporal sites (e.g. Lambroso, 1997; Holmes et al., 2010; 
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Caraballo et al, 2008; Tucker et al., 2007). In addition, studies in EC-hippocampal 
slices have suggested that there is altered excitability and susceptibility to 
epileptogenesis in GAERS (Genetic Absence Epilepsy Rat from Strasbourg; Armand 
et al, 1998; 1999), and it is also the case that local cerebral glucose utilisation is 
increased in limbic regions (including EC) as well frontal and somatosensory areas 
(Nehlig et al., 1998; Carcak et al., 2009) in GAERS.  For these reasons, and 
because our investigations of other anticonvulsants have focussed on this area we 
decided to continue with it in the present study, although we do not suggest that the 
EC may be a primary focus in absence seizures 
 
2. Materials and Methods 
 
2.1. Slice preparation 
 
All experiments were performed in accordance with the U.K. Animals (Scientific 
Procedures) Act 1986, European Communities Council Directive 1986 (86/609/EEC) 
and the University of Bath ethical review document. The number of animals used 
was kept to a minimum and every precaution was taken to minimize any suffering 
and stress inflicted. EC slices were prepared from male Wistar rats (60-100 g) male 
Wistar rats (P28-40) anaesthetised with ketamine (120 mg/kg) plus xylazine (8 
mg/kg). Rats were decapitated and the brain removed and immersed in artificial 
cerebrospinal fluid (aCSF; see below for composition) at 4°C. Slices (400 µM) were 
cut using a Campden Vibroslice and stored in aCSF bubbled with carbogen (95% 
O2/5% CO2) at room temperature. To increase neuronal survival and viability, 
ketamine (4 µM) was included in the cutting solution, and the antioxidants n-acetyl-l-
cysteine (6 µM) and uric acid (100 µM), added to both cutting and storage solutions.  
For patch clamp recordings slices were transferred to a recording chamber perfused 
(2ml/min) with oxygenated aCSF at 31-32°C on an Olympus BX50WI microscope. 
Neurones were visualized using DIC optics and an infrared video camera. In VmD 
experiments slices were transferred to a recording chamber where they were held at 
the interface between a continuous perfusion of oxygenated aCSF (1.5 ml/min) 
maintained at 32 ± 0.5 °C and warm moist carbogen gas. Intracellular recordings 
were made “blind” from slices visualised with a binocular microscope (Wild M8). We 
have found (Woodhall, G.L. and Jones, R.S.G., unpublished observations) that the 
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use of antioxidants produces robust and long-lasting slices, but does not have any 
apparent effect on the pharmacology of glutamate or GABA transmission. 
Nevertheless, in both recording situations slices were allowed to equilibrate in the 
recording chamber for at least 1 hour prior to recording to allow for washout of these 
agents. The perfusion and storage aCSF contained (in mM): NaCl (126), KCl (3.25), 
NaH2PO4 (1.4), NaHCO3 (19), MgSO4 (2), CaCl2 (2), and D-glucose (10). For cutting 
the slices at 3-4oC, NaHCO3 was increased to 25 mM to maintain pH at acceptable 
levels (7.3). 
 
2.2. Whole-cell patch clamp recordings.  
 
Patch pipettes pulled from borosilicate glass were used for recording spontaneous 
EPSCs (sEPSCs). They were filled with a Cs-gluconate based solution containing (in 
mM) D-Gluconate (100), HEPES (40), QX-314 (1), EGTA (0.6), MgCl2 (5), TEA-Cl 
(10), phosphocreatinine (5); ATP-Na (4) and GTP-Na (0.3). To record spontaneous 
(sIPSCs) or miniature (mIPSCs) inhibitory PSCs, the patch solution contained CsCl 
(100), HEPES (40), QX-314 (1), EGTA (0.6), TEA-Cl (10), MgCl2 (5), ATP-Na (4) 
and GTP-Na (0.3). Solutions were adjusted to 275 mOsmol and pH 7.3 with CsOH. 
Whole-cell voltage clamp recordings (holding potential -60 mV) were made from 
pyramidal neurones in layer III of the medial division of the EC, using an Axopatch 
200B amplifier. Signals were filtered at 2 kHz and digitized at 20 kHz. Series 
resistance compensation was not employed, but access resistance (10-30 MΩ) was 
monitored at regular intervals and cells were discarded if it changed by more than 
±10%. Liquid junction potentials (EPSC +12.0 mV; IPSCs +10.2 mV) were estimated 
using pClamp-8 software, and compensated for in the holding potentials. When 
recording IPSCs, AMPA-receptors and NMDA-receptors were blocked with bath 
applied NBQX and 2-AP5, respectively.  
 
Data were recorded using Axoscope software and Minianalysis (Synaptosoft, 
Decatur) was used for analysis of PSCs off-line. Spontaneous events were detected 
using a threshold-crossing algorithm. Cumulative probability distributions of 
interevent interval (IEI) of spontaneous currents were compared using the 
Kolmogorov-Smirnoff test (KS). When data were pooled for this analysis, a minimum 
of 200 events was sampled during a continuous recording period for each neurone 
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under each condition. Mean amplitudes, rise times (10-90%) and total decay times 
were compared using a paired t-test. In some cases, to gain an overall picture of the 
effects of ethosuximide on the level of spontaneous inhibition or excitation, we 
estimated total charge transfer associated with sIPSCs. This is calculated by 
measuring the area of sIPSCs or sEPSCs, and is directly proportional to the 
amplitude multiplied by the decay time (Hollrigel & Soltesz 1997). We determined 
charge transfer associated with sPSCs in a set time period of 2 min in control and in 
the presence of the drug. All error values in the text refer to standard error of the 
mean. 
 
2.3. VmD estimations 
 
Sharp electrodes pulled from borosilicate glass and filled with potassium acetate 
(3M) were used to make intracellular voltage recordings from pyramidal neurones in 
layer III of the medial EC using an Axoprobe 1A amplifier (Molecular Devices, 
Sunnyvale CA, USA) in bridge mode. Once membrane potential was stabilised after 
impalement, estimates of global background excitation (Ebg) and inhibition (Ibg) were 
derived from membrane potential fluctuations using the VmD method at regular 
intervals throughout the recordings. This approach was derived by Rudolph et al., 
(2004) and we have adapted it for recording in EC slices (Greenhill and Jones, 
2007). Briefly, neurones were depolarised (for 15–20 s) by injection of two levels of 
known positive current via the recording electrode. The values of the currents 
differed from neurone to neurone, but were maintained the same throughout any 
individual experiment. One level was chosen to elicit a depolarization to within 1-2 
mV of action potential threshold, and the second was adjusted to depolarize the 
neurone to about half way between this and resting membrane potential. Membrane 
potential fluctuations at these two levels were fitted to Gaussian distributions (using 
Prism 4 software, GraphPad, San Diego, USA) and the mean and variance of the 
membrane potential determined. Leak conductance in each neurone was calculated 
from the ohmic response produced by a small (0.1 nA 100 ms) hyperpolarizing 
current, injected at resting membrane potential. These parameters, together with 
mean reversal potentials for AMPA-receptors and GABAAr mediated synaptic 
responses (derived from preliminary experiments Greenhill and Jones, 2007), 
allowed us to use the VmD relationship to quantify background inhibitory and 
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excitatory conductances resulting from global network input onto individual 
neurones. 
 
Cellular excitability was determined by injecting depolarizing current pulses at resting 
potential during intervals between Ebg and Ibg estimates. Firstly, action potential (AP) 
thresholds were determined using brief incremental peri-threshold injections of 
depolarising current (0.1-1.0 nA, 50 ms) via the recording electrode, with firing 
threshold measured with respect to resting membrane potential. Secondly, trains of 
action potentials were elicited by longer, supra-threshold current pulses (0.2-1.0 nA, 
200 ms), and the number of spikes per pulse determined. Action potential amplitudes 
(from rest) and half-widths were also determined. Statistical analysis (paired t-tests 
or one-way ANOVA) was performed with Prism 4 software. All error values in the text 
refer to standard error of the mean. 
 
2.4. Materials 
 
Salts used in preparation of aCSF were purchased from Merck/BDH or Fisher 
Scientific (UK). All drugs were applied by bath perfusion. The following drugs were 
used: ethosuximide (3-ethyl-3-methyl-pyrrolidine-2,5-dione, Sigma-Aldrich, UK), TTX 
(Alamone Labs, Israel), NBQX (6-nitro-7-sulphamoylbenzo[f]quinoxalone-2,3-dione 
sodium, Tocris, UK), 2-AP5 (2-amino-5-phosphonopentanoic acid, Tocris, UK).  
 
3. Results 
 
The experiments described below were obtained from a total of 40 neurones of the 
medial division of the EC. Cells for intracellular recordings (the VmD method) were 
identified as pyramidal based on their firing characteristics, resting membrane 
potential and response to injected current, using criteria established by a previous 
study employing intracellular recordings and biocytin fills [36]. Whole-cell recordings 
were visualised using IR-DIC optics and cells were selected for their clear pyramidal 
morphology. Ethosuximide was tested at 2 concentrations, 250 and 500 µM, which 
represent the lower and mid-range of the therapeutically relevant plasma 
concentrations respectively (e.g. see Rogawski and Porter, 1990). 
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3.1 Whole-cell Patch Clamp 
 
Ethosuximide had little detectable effect on sEPSCs. In control recordings (n=12) the 
mean IEI was 255±41 ms and this was unaltered (286±31 ms) in the presence of 
ethosuximide (250 µM). Mean amplitude was also unaltered (14.1±1.1 nA v 
13.6±0.9nA). In 7 neurones, ethosuximide was added cumulatively to a 
concentration of 500 µM. In these neurones, mean IEI and amplitude were 271±21 
ms and 12.9±0.7 pA in the presence of ethosuximide at 250 µM, and again neither 
parameter was altered with the higher concentration (288±51 ms and 12.0±1.1 pA). 
Fig. 1A illustrates recordings of sEPSCs in one neurone, and the pooled IEI and 
amplitude data are shown in Fig. 1B. 
 
In contrast to sEPSCs, ethosuximide caused pronounced changes in sIPSCs. In 
control conditions, sIPSCs (n=13) had a mean IEI of 115±21 ms. Addition of 
ethosuximide at 250 μM decreased IEI to 89±9 ms. KS analysis of cumulative 
probability distributions of pooled IEI data showed that the change was significant 
(P<0.001) and it represented an increase in mean frequency from 9.2±2.1 Hz to 
11.4±0.9 Hz. In 6 neurones ethosuximide was increased to 500 µM, and this resulted 
in a further decrease in IEI from 90±13ms to 62±9 ms (11.3±1.2 Hz to 16.2±1.0 Hz) 
and again the change was significant (KS; P<0.001). Respective mean amplitudes 
were 30.1±2.3 pA, 32.5±1.9 pA and 35.1±2.7 pA in control, 250 µM and 500 µM 
ethosuximide, but the changes were not significant (2-way ANOVA). The drug did 
not affect rise time of sIPSCs (not shown), and although decay time tended to be 
slightly longer in the presence of the drug (control 15.3±1.6 ms; ethosuximide (250) 
16.2±1.3 ms; ethosuximide (500) 17.4±1.1 ms), the differences were not significant 
(2-way ANOVA). Recordings in one neurone are illustrated in Fig. 2A. Pooled data 
for IEI and amplitude are illustrated by the graphs in Fig. 2B. 
 
To make an overall comparison of the level of spontaneous GABAergic inhibition we 
estimated the total charge transfer associated with sIPSCs. In control conditions 
charge transfer in a 2 min recording block was 1620±281 pC, and this increased to 
2419±402 pC and 3420±495 pC in the presence of ethosuximide at 250 µM and 500 
µM, respectively. The increase at 250 µM just failed to reach significance, but that at 
500 µM was significant (P<0.05). These data are illustrated in Fig. 2C. 
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 In 4 neurones we determined the effect of ethosuximide (500 µM) on mIPSCs 
recorded in the presence of TTX (1 µM). Mean IEI and amplitude in control 
recordings was 236±42 ms, and 22.9±1.8 pA, reflecting a reduced frequency and 
amplitude of isolated activity-independent release compared to sIPSCs. However, 
ethosuximide was still effective in elevating GABA release, decreasing mean IEI to 
114±32 ms. Mean amplitude of mIPSCs in the presence of the drug were slightly 
larger (25.1±1.3 pA) but, again, the change was not significant. 
 
3.2. VmD studies 
 
Thus, ethosuximide increased spontaneous GABA release, but had little effect on 
spontaneous glutamate release. We next determined whether these changes in 
spontaneous transmitter release reflected global background inhibition or excitation 
by using the VmD approach. 
 
Sharp electrode recordings (n=6) gave an estimated mean global background 
inhibitory conductance or IBg of 5.8±0.6 nS. In contrast, mean EBg, the global 
background excitation was considerably lower at 1.4±0.2 nS. Thus, the mean I:E 
ratio was 4.3±0.3, which is entirely consistent with previous studies showing a 
dominance of inhibition over excitation (Greenhill and Jones, 2007; Rudolph et al., 
2004; 2007). In the presence of ethosuximide (250 µM) IBg increased to 9.1±3.0 nS 
but this just failed to reach significance. Concurrently EBg was unaltered (1.4±0.2 v 
1.2±0.3 nS). However, despite the lack of significant change in either parameter 
individually, there was a significant change in the I:E ratio in favour of inhibition from 
4.3±0.3 to 7.6±1.3 (P<0.05). The changes in global conductances and the I:E ratio 
are summarised in Fig. 3A and C. 
 
In 5 further neurones we tested the effect of ethosuximide at 500 µM (Fig. 3B-D). In 
control conditions IBg was 4.5±0.5 nS and EBg was estimated at 1.3±0.1 nS, giving a 
mean I:E ratio of 3.7±0.3. With the addition of ethosuximide, EBg remained stable at 
1.2±0.2 nS, but IBg increased substantially and significantly to 12.1±2.2 nS (P<0.05, 
paired t-test), resulting in a marked rise in mean I:E ratio to 9.8±1.3.  
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The increase in dominance of global background inhibition over excitation was 
accompanied by evidence of a reduction in cellular excitability, without any 
appreciable change in spike generating mechanisms. Control parameters for 
neurones in studies with either concentration of ethosuximide were similar and so 
are pooled for simplicity. Mean membrane potential in control conditions was -
71.5±0.7 mV. This tended to hyperpolarize with both 250 µM (-73.6±0.6 mV) and 500 
µM ethosuximide (-74.4±0.8 mV), but the changes were not significant. Mean action 
potential amplitude and half-width were 95.6±1.2 mV and 0.51±0.06 ms, 
respectively. These parameters were also unaltered by ethosuximide at either 250 
µM (97.7±1.8 mV, 0.48±0.06 ms) or 500 µM (96.6±2.1 mV, 0.44±0.05 ms). 
Concurrently, however, with the lower concentration, spike firing threshold was 
increased from 21.6±0.9 mV to 25.0±1.2 mV positive to rest (P<0.05), and the 
number of spikes evoked by a 250 ms depolarising pulse was reduced from 4.8±0.2 
to 3.0±0.5 (P < 0.01). The changes were increased further with the higher 
concentration of ethosuximide, with spike threshold elevated to 27.1±1.2 mV positive 
to rest, and the number of spikes evoked by a depolarizing pulse falling to 2.4±0.6. 
The changes in excitability are illustrated for pooled data and in an individual 
neurone in Fig. 3E and F. 
 
4. Discussion 
 
Ethosuximide increased the frequency of sIPSCs in principal neurones in layer III. A 
small increase in amplitude and decay time of sIPSCs may indicate a weak effect at 
postsynaptic GABA receptors, but it is likely that the predominant effect of the drug is 
presynaptically to increase GABA release. The effect was specific to inhibitory 
synapses as sEPSCs were unaltered by ethosuximide. The increase in GABA 
release was reflected by an increase in network driven, global background inhibition 
estimated by the VmD approach. These studies provide a further validation of VmD 
estimations for recording integrated activity in neurones embedded in an active 
synaptic network (Rudolph et al., 2004; Greenhill and Jones, 2007). The combined 
observations demonstrate that increased GABA release at the cellular level is 
reflected by an elevation of global background inhibition, and a shift in balance of 
network bias to reduce excitability. 
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We have previously examined the effects of other anticonvulsants on spontaneous 
background synaptic activity using the same approaches (Cunningham et al, 2000; 
2003; 2004; Cunningham and Jones, 2000; Yang et al, 2007; Greenhill and Jones, 
2010) and the profile of effects varied. Phenytoin, lamotrigine and carbamazepine 
decreased background excitation and concurrently increased inhibition (Cunningham 
et al., 2000; Cunningham and Jones, 2000; Greenhill and Jones, 2010), all three 
drugs increasing I:E ratio. In contrast, gabapentin, pregabalin and felbamate 
decreased excitation but left inhibition intact (Cunningham et al., 2004; Yang et al., 
2007; Greenhill and Jones, 2010), again increasing I:E ratio. Valproate decreased 
the frequency of both sEPSCs and sIPSCs in whole cell patch clamp studies but it 
prolonged the decay time of sIPSCs so, overall, synaptic inhibition and IBg were 
effectively increased (Cunningham et al., 2000; Greenhill and Jones, 2010) with a 
consequent increase I:E ratio. Finally, the GABA uptake blocker, tiagabine 
decreased sIPSC frequency but increased both amplitude and decay time, again 
effectively increasing IBg. It concurrently increased sEPSC frequency and, thus, 
weakly increased EBg (Greenhill and Jones, 2010), but overall, it also increased I:E 
ratio. The current observations reveal a new spectrum of effects with ethosuximide, 
but again, as with the other drugs investigated, I:E ratio was increased.  
 
Thus, despite the varying profile of effects and regardless of the (putative) molecular 
targets of the different drugs (e.g. see Loscher and Rogawski, 2004; White et al., 
2007) they all increased global I:E ratio demonstrating a biasing of global network 
activity in favour of inhibition. Concurrently, cellular excitability was decreased by all 
the anticonvulsants (Greenhill and Jones, 2010), although any connection between 
these effects remains circumstantial at present. However, there is a considerable 
literature suggesting that background network activity is instrumental in determining 
neuronal excitability and gain (see Jones and Woodhall, 2005; Greenhill and Jones, 
2007; and refs therein). Thus, it is possible that a common end point of therapeutic 
intervention is to decrease neuronal excitability and synchronisation, irrespective of 
the primary molecular target. It is interesting that somatosensory cortical neurones in 
GAERS display a depolarized membrane potential and high firing rate, and 
ethosuximide, concurrent with abolition of spike-wave discharges, restored 
membrane potential and firing rate to that seen in normal control animals (Polack 
and Charpier, 2009). In our experiments, ethosuximide tended to hyperpolarize EC 
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neurones (but not significantly) and we did see a clear reduction in excitability. Thus, 
it is tempting to speculate that the reduced excitability seen with ethosuximide in the 
GAERS (Polack and Charpier, 2009) may be linked to increased background release 
of GABA.  
 
Do our observations in concord with previous studies of the effect of ethosuximide on 
glutamate and GABA systems? Early evidence suggested that the reduction in 
GABA levels subsequent to GAD inhibition in mouse brain could be reversed beyond 
control levels by ethosuximide (Löscher and Frey, 1977). Ethosuximide alone 
increased rat whole brain and frontal cortical GABA-levels (Linn-Michell et al., 1986; 
Ponnusamy and Pradhan, 2006), which could accord with an increased release of 
GABA. However, it had no effect on spontaneous or stimulated release of GABA in 
rat cortical slices (Skeritt and Johnson, 1983; Crowder and Bradford, 1987) and did 
not alter extracellular GABA concentrations in motor cortex in vivo (Terzioglu et al., 
2006). Although these studies conflict with the increase in GABA release that we 
see, they used large-scale approaches to look at release, and may not detect subtle 
changes at the cellular level. Some evidence also suggests that high concentrations 
of ethosuximide may weakly block GABAAr in cortical and thalamic neurones 
(Barnes and Dichter, 1984; Coulter et al., 1990), which contrasts with the trend 
towards an increased amplitude of mIPSCs and sIPSCs seen in our studies. Finally, 
there is evidence that ethosuximide may block GABA uptake (Rainesalo et al., 
2004). Such an effect could conceivably be reflected as an increase in GABA 
release at inhibitory synapses (cf tiagabine; Greenhill and Jones, 2010). As with 
GABA, glutamate release in cortical slices and in motor cortex in vivo was unaffected 
by ethosuximide (Skerrit and Johnson, 1983; Crowder and Bradford, 1987; Terzioglu 
et al., 2006), and chronic administration of the drug had no effect on glutamate levels 
in frontal cortex or hippocampus (Ponnusamy and Pradhan, 2006). These results 
agree with ours that suggest that glutamate release is unaffected by ethosuximide 
(but see discussion concerning Huang et al. (2011) below). 
 
We have not studied the molecular targets of ethosuximide, but some discussion is 
warranted. It has been suggested that T-type Ca2+ channels in thalamo-cortical 
neurones are a primary target of ethosuximide (Coulter et al., 1989a,b; Kostyuk et 
al., 1992; MacDonald and Kelly, 1994; Gomora et al., 2001), blockade of which is 
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proposed to reduce oscillatory burst firing and the consequent drive to spike-wave 
discharges in the cortex. Other evidence suggested that somatic T-type currents are 
weakly blocked by ethosuximide  (Thompson and Wong, 1991; Sayer et al., 1993; 
Leresche et al., 1998) so such a mechanism of action is equivocal. It is possible that 
an action at T-type channels could be involved in the effects of ethosuximide on 
GABA-release. At least one subtype of T-type channel (CaV3.3) is localised to soma 
and dendrites of calbindin and parvalbumin containing interneurones in mouse 
somatosensory cortex (Liu et al., 2011). However, if ethosuximide were blocking 
equivalent channels in the EC we might expect a decreased interneurone excitability 
and firing, and a consequent decrease in GABA release rather than an increase. 
Since ethosuximide also increased the activity independent release of GABA, this 
largely rules out an interaction with somato-dendritic channels. T-type Ca-channels 
do not appear to be located on presynaptic inhibitory terminals in somatosensory 
cortex (CaV3.3, Lui et al., 2011) or in layer III of the EC (CaV3.2, Huang et al., 2011) 
and, in any case, it would be difficult to reconcile a blockade of these channels with 
the increase in GABA release we observe.  
 
Persistent Na-channels, Ca-activated K-channels and GIRKs (Leresche et al., 1998; 
Kobayashi et al., 2009) may also be blocked by ethosuximide. Blockade of soma-
dendritic K-channels in interneurones could potentially lead to increased tonic firing 
and elevated GABA release but the increase in activity independent release seems 
to rule out this possibility. It is possible that an effect on GIRKs in inhibitory terminals 
could elicit an increase in GABA release. For example, we have shown that GABA 
release at inhibitory terminals in the EC can be depressed by GABAB-receptors 
(GABABr; Bailey et al., 2004), and this could involve activation of GIRKs. GABABr 
can be tonically activated by ambient GABA (Bailey et al., 2004), so if ethosuximide 
was to block the GIRK linked to this receptor, it could result in a reduction in tonic 
depression of GABA release, manifested as an increase. Such a possibility deserves 
investigation. 
 
We found no change in glutamate release with ethosuximide, but it should be noted 
that T-type channels (CaV3.2) have been located at excitatory terminals in layer III of 
the EC, where they can, under some circumstances, enhance glutamate release 
(Huang et al., 2011). This study suggests that the channels may be inactivated under 
  14
resting conditions, and may contribute to release only when terminals are 
hyperpolarized (Huang et al., 2011). Our studies suggest that even if these channels 
were blocked by ethosuximide this may be of minor consequence under resting 
conditions, since glutamate release was unaffected. It is possible is that 
ethosuximide could reduce glutamate release by blocking presynaptic channels 
when terminals are hyperpolarized, but the circumstances under which this might 
occur conjectural. Nevertheless, it is interesting that blockade of T-type channels by 
ethosuximide may be stronger at hyperpolarised potentials (Coulter et al., 1989b).  
 
Our experiments have been conducted in normal tissue so we need to ask is 
whether the results have relevance to the epileptic situation. Stringer (1996) showed 
that pentylenetetrazole, which blocks the GABAAr (Huang et al., 2001), enhanced the 
spread of evoked epileptiform activity from the EC to the hippocampus in vivo. The 
enhancement was attenuated by ethosuximide, and this occurred via an action of the 
drug on the EC itself (Stringer, 1996). One explanation for this could be that 
increased GABA release elicited by ethosuximide could overcome the competitive 
block (Huang et al., 2001) of GABA receptors by pentylenetetrazole. Of profound 
interest are studies in a mouse model of familial absence epilepsy (Tan et al., 2007). 
Mice heterozygous for a point mutation in the GABAAr γ2-subunit showed 
spontaneous cortical spike-wave absence seizures. The seizures were accompanied 
by a reduction in amplitude of mIPSCs in layer 2/3 of the cortex. Although the study 
did not investigate the effects of ethosuximide on spontaneous inhibition, the drug 
ameliorated the spike-wave discharges. It seems possible that ethosuximide could 
be acting by increasing GABA release in similar way to that we report here, thus 
reversing the decreased cortical inhibition seen in the mutant mice.  
 
It is worth considering some paradoxical aspects of our findings. Ethosuximide is 
therapeutically specific for generalized absence seizures, and may precipitate or 
exacerbate tonic–clonic partial and generalized seizures (Perucca et al., 1998; 
Chaves and Sander, 2005). Yet, in common with drugs that target the latter, it 
increased the ratio of background synaptic inhibition to excitation in cortical neurones 
(Greenhill and Jones, 2010). It seems likely that a generalised increase in cortical 
background inhibition is important for anticonvulsant actions, but therapeutic 
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specificity for particular types of epilepsy is also conferred by concurrent actions at 
other molecular targets and locations. In the case of ethosuximide, a combination of 
increased cortical inhibition may require concurrent modulation of thalamo-thalamo, 
cortico-thalamo and thalamo cortical interactions (Manning et al., 2003) for the drug 
to exert its overall anti-absence effects.
  16
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Figure legends 
 
Fig. 1: Ethosuximide (ETX) has no effect on spontaneous glutamate release. A. 
Whole-cell patch-clamp recordings of sEPSCs from a layer III pyramidal cell in the 
EC. Application of ethosuximide had no effect at either 250 µM or 500 µM. B. Pooled 
data (at least 200 events in each cell in each recording condition) in 12 neurones in 
250 µM and 7 neurones with 500 µM. Control data for the two drug groups have 
been pooled for simplicity. Cumulative probability for IEI and amplitude distributions 
show complete overlap, illustrating the lack of effect of the drug. 
 
Fig. 2: Ethosuximide (ETX) increases spontaneous GABA release. A. Whole-cell 
patch-clamp recordings of sIPSCs from a layer III pyramidal cell in the EC. 
Ethosuximide caused an increase in frequency of sIPSCs, which was more marked 
at the higher concentration (500 µM). In this neurone there appeared to be an 
increase in larger amplitude events as well. B. Pooled data (at least 200 events in 
each cell in each recording condition) reflect these changes, with a concentration- 
related leftward shift in cumulative probability distribution of IEI, reflecting the 
increased frequency. There was a slight rightward shift in amplitude distribution at 
500 µM, but this did not reach significance. C. The changes in sIPSCs were reflected 
by a clear increase in the total inhibitory charge transfer, and again this was 
concentration-related. 
 
Fig 3. Ethosuximide (ETX) increased global background inhibition but not excitation. 
A. The graphs show mean data for global background synaptic activity. At 250 µM, 
ethosuximide non-significantly enhanced background inhibition together with a slight, 
but again non-significant fall in excitation. B. Ethosuximide at 500 µM had similar, but 
more marked effects, with the increase in IBg reaching significance. C. The combined 
effect of these changes resulted in a doubling of the I:E ratio in the presence of the 
drug which was significant at both concentrations. D. The traces are sharp electrode 
recordings taken at resting potential (Em) and at two levels of induced depolarization 
used to determine VmD (see Greenhill and Jones , 2007) E. Concurrent with the 
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effects of ethosuximide on global synaptic conductances there was no apparent 
change in spike generation mechanisms (no effect on amplitude or half width), but 
spike threshold was significantly increased and the number of spikes elicited by a 
200 ms depolarizing current pulse was reduced. F. Intracellular recordings from one 
neurone illustrating the excitability changes. On the left, a short depolarizing current 
pulse was used to elicit a single pulse, and in the presence of ethosuximide this had 
to be increased to overcome the elevated spike threshold. On the right, equivalent 
depolarizing pulses elicited a series of 5 spikes in control but only 2 in the presence 
of the drug. 
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